Biosimilars
Specialty Channel

Featured Article
What, according to the FDA, makes a biologic drug a biosimilar?
The FDA has approved trastuzumab-anns as a biosimilar to trastuzumab.
Oncology Learning Network provides a brief overview of oncology and oncology supportive biosimilars that have been approved to date.
The FDA has approved a biosimilar to trastuzumab for the treatment of patients with HER2-overexpressing breast cancer.
A biosimilar to rituximab is well-tolerated and just as effective as its reference drug in patients with low-tumor burden FL.
The FDA approved a biosimilar that can decrease the occurrence of infections, as manifested by febrile neutropenia.
The FDA has granted approval to a biosimilar of a common drug used for the treatment of patients experiencing chemotherapy-related neutropenia.
Mylan NV on Monday beat a clutch of drugmakers racing to get a biosimilar to Amgen Inc's blockbuster drug, Neulasta, to market.
The US Food and Drug administration approved a biosimilar for the treatment of anemia caused by chemotherapy or chronic kidney disease.

News

The FDA has approved trastuzumab-anns as a biosimilar to trastuzumab.
Oncology Learning Network provides a brief overview of oncology and oncology supportive biosimilars that have been approved to date.
The FDA has approved a biosimilar to trastuzumab for the treatment of patients with HER2-overexpressing breast cancer.
A biosimilar to rituximab is well-tolerated and just as effective as its reference drug in patients with low-tumor burden FL.

Interactive Features

What, according to the FDA, makes a biologic drug a biosimilar?
Stay in the know.
OncNet Newsletter